Lizarzaburu-Robles Juan Carlos, Garro-Mendiola Alonso, Lazo-Porras María, Sanz-Pastor Alba Galdón, Vento Flor, Lorenzo Oscar
Endocrinology Unit, Hospital Central de la Fuerza Aérea del Perú (HCFAP), Lima, Perú; Doctorate Program in Medicine and Surgery, Escuela de Doctorado Universidad Autónoma de Madrid, Madrid, Spain.
Endocrinology Unit, Hospital Central de la Fuerza Aérea del Perú (HCFAP), Lima, Perú.
Endocr Pract. 2024 Dec;30(12):1134-1140. doi: 10.1016/j.eprac.2024.09.011. Epub 2024 Sep 25.
To compare the 1-hour postload glucose (1h-PG) value of an oral glucose tolerance test (OGTT) with the metabolic syndrome (MetS) and the Finish Diabetes Risk Score (FINDRISC) in patients with impaired fasting glucose (IFG) to predict type 2 diabetes mellitus (T2DM).
A cohort study was conducted in patients at a general hospital in Lima, Perú. An OGTT was performed in subjects with IFG who were followed-up for 7 years for T2DM development. The exposure variables were 1h-PG ≥ 155 mg/dL, MetS, and a FINDRISC ≥ 13 points, and the outcome was the presence of T2DM. The relative risk, confidence interval, and area under the curve (AU) were also estimated.
Among 324 subjects with IFG, 218 completed the 7-year follow-up. The mean age was 56.2 ± 11.5 years, 64.0% were woman, and 63.8% were overweight/obese. Of these, 36.8% had 1h-PG ≥ 155 mg/dL and normal glucose tolerance, 66.8% had MetS, and 64.5% had FINDRISC ≥ 13 points. After 7 years, 21.1% of participants developed T2DM, with 68.8% of them who had 1h-PG ≥ 155 mg/dL (P < .001), 62.2% had MetS (P = .013), and 67.9% had FINDRISC ≥ 13 (P = .68). After adjusting by age, sex, and body mass index, the relative risk was 3.52 (1.64-7.54; 95% CI), 1.81 (0.96-3.38; 95% CI), and 1.17 (0.51-2.70; 95% CI) for each exposure variable, respectively. Also, the AU was 0.72 (0.60-0.83), 0.63 (0.51-0.75), and 0.51 (0.38-0.63) (P = .01), respectively.
By performing an OGTT in patients with IFG, an 1h-PG ≥ 155 mg/dL value may be helpful to predict T2DM at 7 years better than the use of MetS or the FINDRISC.
比较空腹血糖受损（IFG）患者口服葡萄糖耐量试验（OGTT）的1小时负荷后血糖（1h - PG）值与代谢综合征（MetS）及芬兰糖尿病风险评分（FINDRISC），以预测2型糖尿病（T2DM）。
在秘鲁利马一家综合医院的患者中进行了一项队列研究。对IFG受试者进行OGTT，并随访7年观察T2DM的发生情况。暴露变量为1h - PG≥155mg/dL、MetS以及FINDRISC≥13分，结局为是否存在T2DM。还估计了相对风险、置信区间和曲线下面积（AU）。
在324例IFG受试者中，218例完成了7年随访。平均年龄为56.2±11.5岁，64.0%为女性，63.8%为超重/肥胖。其中，36.8%的人1h - PG≥155mg/dL且糖耐量正常，66.8%患有MetS，64.5%的FINDRISC≥13分。7年后，21.1%的参与者患T2DM，其中68.8%的人1h - PG≥155mg/dL（P<.001），62.2%患有MetS（P = .013），67.9%的FINDRISC≥13（P = .68）。在按年龄、性别和体重指数进行调整后，每个暴露变量的相对风险分别为3.52（1.64 - 7.54；95%CI）、1.81（0.96 - 3.38；95%CI）和1.17（0.51 - 2.70；95%CI）。此外，AU分别为0.72（0.60 - 0.83）、0.63（0.51 - 0.75）和0.51（0.38 - 0.63）（P = .01）。
对IFG患者进行OGTT时，1h - PG≥155mg/dL的值可能比使用MetS或FINDRISC更有助于预测7年后的T2DM。
